The epithelial-mesenchymal transition (EMT) is emerging as a critical factor for the progression and metastasis of carcinomas, as well as drug resistance. The T-box transcription factor Brachyury has been recently characterized as a driver of EMT in human carcinoma cells. The purpose of this study was to characterize Brachyury as a potential target for lung cancer therapy.
Roselli, M., Fernando, R., Guadagni, F., Spila, A., Alessandroni, J., Palmirotta, R., et al. (2012). Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. CLINICAL CANCER RESEARCH, 18(14), 3868-3879 [10.1158/1078-0432.CCR-11-3211].
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer
ROSELLI, MARIO;
2012-07-15
Abstract
The epithelial-mesenchymal transition (EMT) is emerging as a critical factor for the progression and metastasis of carcinomas, as well as drug resistance. The T-box transcription factor Brachyury has been recently characterized as a driver of EMT in human carcinoma cells. The purpose of this study was to characterize Brachyury as a potential target for lung cancer therapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
Roselli, Clin Cancer Res 2012.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
3.9 MB
Formato
Adobe PDF
|
3.9 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
